VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2007 by Hadassah Medical Organization.
Recruitment status was  Not yet recruiting
Information provided by:
Hadassah Medical Organization Identifier:
First received: November 25, 2007
Last updated: November 26, 2007
Last verified: November 2007
We hypothesize that misexpression of vascular endothelial growth factor (VEGF) in the CSF of preterm infants can be used as a biomarker to predict the risk for developming white matter damage.

Preterm Infants With White Matter Damage
Preterm Infants Developing Normally

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants

Further study details as provided by Hadassah Medical Organization:

Biospecimen Retention:   Samples Without DNA

Estimated Enrollment: 40
Study Start Date: January 2008
Estimated Study Completion Date: January 2009


Ages Eligible for Study:   25 Weeks to 40 Weeks
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
preterm infants.

Inclusion Criteria:

  • Preterm infants undergoing lumbar puncture.

Exclusion Criteria:

  • Preterm with IVH or known infection or meningitis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00564161

Contact: Talya Dor, MD 972-50-8946-704
Contact: Itai Berger, MD

Sponsors and Collaborators
Hadassah Medical Organization
Principal Investigator: Talya Dor, MD Hadassah Medical Organization
  More Information

No publications provided Identifier: NCT00564161     History of Changes
Other Study ID Numbers: 606060-HMO-CTIL, 606060-HMO-CTIL
Study First Received: November 25, 2007
Last Updated: November 26, 2007
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration processed this record on November 27, 2015